ライフサイエンスコーパス: complete response

1 ly HCC recurrence (defined as 365 days after complete response).

2 timated to be 65% (79% among patients with a complete response).

3 responded in patients with partial response/complete response).

4 The ORR was 85.5% (94 of 110 patients; n = 1 complete response).

5 only a small percentage of patients achieves complete response.

6 nts, including two partial responses and one complete response.

7 on was 72%, including 19 patients (59%) with complete response.

8 nse, and eight (21%, 95% CI 9-36) achieved a complete response.

9 ncluding 9 (3.1%) who experienced pathologic complete response.

10 nse, and nine (45%, 95% CI 23-68) achieved a complete response.

11 ad an objective response, and 59 (58%) had a complete response.

12 sponse and 11 (26%, 95% CI 14-42) achieved a complete response.

13 onse, and one (5%, 95% CI 0.1-24) achieved a complete response.

14 n 48 patients (60%), including 17 (21%) with complete response.

15 are independently associated with pathologic complete response.

16 tive tracking of M-proteins in patients with complete response.

17 ts, 85% had an objective response; 59% had a complete response.

18 n 35 (78%) of 45 patients; 24 (53%) achieved complete response.

19 ctive response; 67% (95% CI, 53 to 78) had a complete response.

20 Four patients, two in each cohort, had complete responses.

21 153 evaluable patients, with 24 (16%) having complete responses.

22 overall response, including 19 (26.8%) with complete responses.

23 most strikingly in patients who had achieved complete responses.

24 tion of objective responses and pathological complete responses.

25 44% (95% CI, 35.1% to 53.2%), including 12% complete responses.

26 ponse rate for all patients was 46% with 17% complete responses.

27 te was 85%, including 15 patients (45%) with complete responses.

28 Best responses were 8 partial and 8 complete responses.

29 CI, 26% to 58%), including 13 partial and 3 complete responses.

30 sus 33% of high-grade tumors (grade 3 or 4) (complete response, 0%; partial response, 33%; SD or DP,

31 tumor characteristics, and AJCC scores (0 = complete response; 1 = isolated tumor cells remaining; 2

32 small-cell lung, and breast cancers, 1 had a complete response, 11 had partial responses, and 66 had

33 among 21 patients in KEYNOTE-013 and 45% (7 complete responses; 13%) among 53 patients in KEYNOTE-17

34 7% of patients achieving a PR or better (11% complete response, 18% very good PR).

35 42 patients treated with nivolumab who had a complete response (20%), 88% (37 of 42) were alive as of

36 ometric mean absorbed dose was found between complete response (232 Gy; 95% confidence interval [CI],

37 esponse rate (ORR) to pembrolizumab was 56% (complete response [24%] plus partial response [32%]; 95%

38 luding 5 partial, 5 very good partial, and 2 complete responses, 3 of which were ongoing at 11, 14, a

39 se rate was 34.3% (95% CI, 25.3% to 44.2%; 4 complete responses, 32 partial responses), and disease c

40 The objective response rate was 48% (7 complete responses; 33%) among 21 patients in KEYNOTE-01

41 interval, 19 to 35), including two stringent complete responses; 39% of patients had a minimal respon

42 -term treatment response in 87% of patients (complete response, 49%; partial response, 38%; stable di

43 Best ORR at any time was 73.2% (complete response, 56.3%).

44 on-cryopreserved infusion (n = 12) was 100% (complete response, 92%; partial response, 8%).

45 ain metastasis response (partial response or complete response, according to mRECIST).

46 quite effective in nonsevere cases (clinical complete response achieved in 13/31 patients).

47 ximately 15%-30% of patients with a clinical complete response after (chemo) radiotherapy who undergo

48 ts of rectal cancer patients with a clinical complete response after (chemo) radiotherapy.

49 id, or clear cell ovarian cancer in clinical complete response after a combination of surgery and fiv

50 months of pembrolizumab or discontinued with complete response after at least 6 months of pembrolizum

51 s with esophageal cancer show pathologically complete response after nCRT according to CROSS regimen,

52 ients with rectal cancer who have a clinical complete response after neoadjuvant chemoradiotherapy.

53 e-scale registry of patients with a clinical complete response after neoadjuvant chemotherapy who hav

54 years) with rectal cancer who had a clinical complete response after neoadjuvant chemotherapy, and wh

55 GPR) or better and 33.3% achieving stringent complete response after transplantation at a median foll

56 bined rate of complete response and clinical complete response among patients who had not received pr

57 end of the 19-week chemotherapy protocol (8 Complete Response and 11 Progressive Disease) were evalu

58 an objective response: 34 (43%; 32-54) had a complete response and 14 (18%; 10-28) had a partial resp

59 s, as of Aug 1, 2017, one (2%) patient had a complete response and 17 (30%) had partial responses; th

60 /127; 95% CI 20.7-37.0); 15 (12%) achieved a complete response and 21 (17%) a partial response.

61 erall response was ten (13%) patients with a complete response and 24 (31%) with a partial response.

62 esponse rate was 52% (9 of 17) (6% [1 of 17] complete response and 46% [8 of 17] partial response), w

63 e thresholds (CSTTs), as well as on rates of complete response and adverse events.

64 The primary outcome was the combined rate of complete response and clinical complete response among p

65 The ORR was 18%, including one confirmed complete response and five confirmed partial responses.

66 ate was 19%, including three patients with a complete response and five with a partial response.

67 s an effective treatment with a high rate of complete response and local disease control according to

68 and an ARID1A mutation, achieved RECISTv1.1 complete response and maintained this response, with a p

69 d) significantly improved rates of stringent complete response and progression-free survival versus b

70 , 113-191 Gy; n = 28) (P = 0.01) and between complete response and progressive disease (117 Gy; 95% C

71 hieved an overall response; four (15%) had a complete response and seven (27%) had a partial response

72 luable patients in cohort one, there was one complete response and seven partial responses (objective

73 The criteria used for defining a clinical complete response and the specific surveillance strategi

74 A complete response and undetectable minimal residual dise

75 At 8 weeks, 38 complete responses and 16 partial responses had been ach

76 objective response, of which four (7%) were complete responses and 27 (50%) partial reponses.

77 ements achieved an objective response (three complete responses and 35 partial responses).

78 ents had an overall response, with five (9%) complete responses and 44 (79%) partial responses.

79 There were 7 complete responses and 8 partial responses to combinatio

80 Overall response rate was 77% (15 complete responses and 8 partial responses) in 30 evalua

81 While some patients achieve complete responses and disease remission, others are com

82 Tumours (RECIST) version 1.1, including two complete responses and eight partial responses.

83 The primary endpoint was objective response (complete responses and partial responses per RECIST 1.1)

84 The overall response rate was 38% with two complete responses and seven partial responses.

85 At 1 year, 4 patients had a complete response, and 3 had a partial response.

86 Twelve patients had complete response, and 35 patients had residual disease.

87 n overall response at day 28, 14 (64%) had a complete response, and 4 (18%) had a partial response.

88 at end of treatment (51 [77%] patients had a complete response, and eight [12%] patients had a partia

89 complete response, partial response, marrow complete response, and haematological improvement) asses

90 levels in cases associated with pathological complete response, and identify potential causes of trea

91 utologous stem-cell transplantation having a complete response, and might represent a new therapeutic

92 hese, five patients experienced MRD-negative complete responses, and 1 had a partial response, and 1

93 interval, 41 to 62); 40% of the patients had complete responses, and 12% had partial responses.

94 Another 90 days later reoccurance or complete response are detected by volume perfusion compu

95 ific objective response (partial response or complete response), as assessed by the local site and su

96 The primary endpoint of part 1 was stringent complete response assessed 100 days after transplantatio

97 e proportion of patients with a pathological complete response, assessed by a central pathology revie

98 he per-protocol population, was pathological complete response, assessed via specimens obtained durin

99 mong the complete responders, 5 maintained a complete response at 16 months, and 3 who stopped treatm

100 AUC = 0.916) for prediction of objective and complete response at 6 weeks, respectively.

101 on was selected as the optimal predictor for complete response at 6-12 months (AUC = 0.857).

102 The primary endpoint was complete response at any time in patients with carcinoma

103 regimen as initial therapy, and 18% were in complete response at enrollment.

104 (59%, 95% CI 47-71; p<0.0001) patients had a complete response at the primary disease evaluation visi

105 0, respectively, or payment only for initial complete response (at current prices) would allow axi-ce

106 nse rate was 70%, including 50% MRD-negative complete responses, at 400 mug/d, the MTD for this study

107 nt differences were observed in pathological complete response between the two groups, either in the

108 y 186 (73%, 95% CI 66.8-78.0) patients and a complete response by 136 (53%, 46.8-59.4).

109 Patients who achieved a complete response by positron emission tomography/comput

110 ents with esophageal cancer and a clinically complete response (cCR) after neoadjuvant chemoradiother

111 tients with esophageal cancer and clinically complete response (cCR) after neoadjuvant chemoradiother

112 response, the following criteria were used: complete response (complete resolution of symptoms attri

113 9 [60%] of 48) patients, including stringent complete response/complete response (4 [8%]), very good

114 Achieving a pathologic complete response confers a significant survival benefit

115 CI], 58%-97%), with 50% of patients having a complete response (CR) (95% CI, 43%-57%); respective res

116 r relies on the identification of a clinical complete response (CR) after neoadjuvant (chemo)radiothe

117 r activity in metastatic melanoma, including complete response (CR) in about 15% of patients.

118 Patients achieving complete response (CR) on PET scan following cycle 2 of

119 t was the proportion of patients achieving a complete response (CR) or a very good partial response (

120 Patients who achieved a complete response (CR) or partial response (PR) with or

121 Seventeen of 58 evaluable patients achieved complete response (CR) or partial response (PR).

122 int was the 2007 international working group complete response (CR) rate after induction.

123 Efficacy was defined as complete response (CR) rate on end-of-treatment (EOT) im

124 The primary objective was to compare complete response (CR) rates (no vomiting and no rescue

125 In the mITT population, the best overall and complete response (CR) rates were 70% and 50%, respectiv

126 were 87.5% (R-CHOP and G-CHOP combinations); complete response (CR) rates were 79.2% and 78.1%, respe

127 Patients who achieved a complete response (CR) received consolidation CRT to 64

128 patients who had a partial response (PR) and complete response (CR) to their last platinum-based ther

129 Overall survival for patients with complete response (CR) was calculated from time of CR.

130 ts with a confirmed partial response (PR) or complete response (CR) within 6 months discontinued nivo

131 9% (95% CI, 45.4% to 74.9%), consisting of 1 complete response (CR), 2 CRs in target lesions, 25 part

132 the proportion of participants who showed a complete response (CR), overall response (OR) and overal

133 ore lymphoma diagnosis, at diagnosis, and at complete response (CR).

134 xation electrophoresis for classification of complete response (CR).

135 ective response rate of 65%, including a 32% complete response (CR).

136 sidered a response as either partial (PR) or complete response (CR).

137 l response rate (ORR) was 29%, including 11% complete response (CR).

138 The primary end point was complete response (CR).

139 2 trial to estimate the difference in day 28 complete response (CR)/partial response (PR) rates for s

140 Primary end point was complete response (CR)/unconfirmed CR (CRu) rate at 6 mo

141 nse rate (intent-to-treat) was 65%, with 49% complete response (CR)/very good partial response/low dF

142 Best responses included 20 complete response (CR; 54%), 5 CR with partial recovery

143 ofovir-unresponsive patients and resulted in complete responses (CR) despite significant lymphopenia

144 ts, the overall response rate (ORR) was 44% (complete response [CR], 28%); among them, the ORR was 65

145 Overall best response rate was 95% in R/R (complete response [CR]/CR with incomplete marrow recover

146 nts were similar in the two groups: ORR 16% (complete response [CR]/partial responses[PRs], 32) versu

147 ve response rate (ORR) of 78%, including 44% complete responses (CRs).

148 ) has been undervalued due to the absence of complete responses, even though patients who develop ear

149 Activity (complete response, expected to occur in >15% of patients

150 No patient with complete response experienced progression, including 2 p

151 years if a patient had a sustained clinical complete response for 1 year was 88.1% (95% CI 85.8-90.9

152 enced progression, including 2 patients with complete response for at least 1 year off therapy.

153 Six of the 15 patients who had a complete response have had a relapse.

154 While a variety of protocols achieved a complete response in >50% of treated mice, the complete

155 patients undergoing surgery, with pathologic complete response in 13 patients (34%).

156 49 patients achieved a response, including a complete response in 25 (51%) of 49 patients.

157 A single injection of 148 kBq induced a complete response in 6 of 7 tumors, with no apparent tox

158 dose of 148 kBq of (225)Ac-RPS-074 induced a complete response in 86% of tumors, with tumor-to-normal

159 these agents is associated with pathological complete response in a spectrum of tumors, including uro

160 Co-primary endpoints were pathological complete response in all-randomised (ie, all randomly as

161 opsy (VAB) to reliably diagnose a pathologic complete response in the breast (pCR-B).

162 east MRI and a locally assessed pathological complete response in the breast and axilla (ypT0/Tis, yp

163 one-third of patients have a pathologically complete response in the resection specimen.

164 ystemic treatment (NST) elicits a pathologic complete response in up to 80% of women with breast canc

165 roup and 50.6% in the NIVO1+IPI3 group, with complete responses in 15.0% and 13.5% of patients, respe

166 ression of all xenografts, including durable complete responses in 50% of mice.

167 ses to express leptin in tumor cells induced complete responses in tumor-bearing mice and supported m

168 different IC harmonised into 4-point scales (complete response, indeterminate, partial response, prog

169 Complete response (n = 0), partial response (n = 8), or

170 Complete response (n = 0), partial response (n = 9), or

171 nt level, metabolic response was as follows: complete response, n = 1; partial response, n = 11; stab

172 A complete response occurred in 109 patients (19%) and was

173 to-treat population had achieved a stringent complete response (odds ratio 1.60, 95% CI 1.21-2.12, p=

174 We also observed pathological complete response of 37.5% and downstaging to pT1 or les

175 dafitinib to palbociclib/fulvestrant induced complete responses of FGFR1-amplified/ER+ patient-derive

176 642 contacted clinicians (n = 977) submitted complete responses, of whom 874 met study inclusion crit

177 ditional 2 years after sustaining a clinical complete response or being distant metastasis-free for 1

178 (8.5-20.1) and seven (5%) patients reporting complete response or better (1.9-9.5).

179 The percentage of patients with a complete response or better was 47.6% in the daratumumab

180 versus 141 (26%) in the VTd group achieved a complete response or better, and 346 (64%) of 543 versus

181 14 (67%) of 21 patients had a complete response or complete response with incomplete h

182 The primary end point was pathologic complete response or minimal residual disease (residual

183 The pathologic complete response or minimal residual disease rate was 3

184 The primary end point was overall response (complete response or partial response) at day 28.

185 of patients achieving an objective response (complete response or partial response), as assessed by t

186 In addition, absence of complete response or very good partial response at day 2

187 Patients who had not achieved a clinical complete response or who had undergone any surgical proc

188 8 to 8.3 months); and clinical benefit rate (complete response + partial response + stable disease >/

189 us letrozole and letrozole groups ( P = .20; complete response + partial response, 54.3% v 49.5%), an

190 Complete response, partial response, and stable disease

191 ndpoint was overall response (a composite of complete response, partial response, marrow complete res

192 Overall response will be defined as complete response, partial response, minor response, sta

193 e assignment of individual response classes (complete response, partial response, progressive disease

194 or augmenting early prediction of pathologic complete response (pCR) and recurrence-free survival (RF

195 off point differentiating between pathologic complete response (pCR) and the non pCR was 1.95.

196 pathologic response, considering pathologic complete response (pCR) as the complete absence of any r

197 ctive was to estimate the rate of pathologic complete response (pCR) at the time of surgery in each o

198 urrence in patients achieving a pathological complete response (pCR) following neoadjuvant chemoradia

199 Pathologic complete response (pCR) following neoadjuvant therapy ha

200 Pathologic complete response (pCR) has been shown to be associated

201 urgery establishes a considerable pathologic complete response (pCR) in EC.

202 he aim was to investigate whether pathologic complete response (pCR) in the breast is correlated with

203 e the association between MSI and pathologic complete response (pCR) in this patient population.

204 icenter, phase II trial comparing pathologic complete response (pCR) rates (ypT0/is, N0) after neoadj

205 in Early Breast Cancer) compares pathologic complete response (pCR) rates of T-DM1 versus trastuzuma

206 ict which patients will achieve pathological complete response (pCR) to neoadjuvant chemotherapy (NAC

207 y regulated in tumors achieving pathological complete response (pCR) to neoadjuvant chemotherapy.

208 computed tomography would predict pathologic complete response (pCR) to neoadjuvant pertuzumab and tr

209 se tumors would go on to have a pathological complete response (pCR), but then rose significantly bef

210 nt surgery, 17 (47.2%) achieved a pathologic complete response (pCR).

211 and -G were correlated with the pathological complete response (pCR).

212 eoadjuvant chemotherapy increased pathologic complete response (pCR).

213 The primary end point is pathologic complete response (pCR).

214 t some patients with severe disease lacked a complete response, prompting us to propose early interve

215 gh-risk disease R-Mono conferred an inferior complete response rate (21% versus 68%; P = 0.006), albe

216 The primary outcome was radiologic complete response rate (CRR) per RECIST; secondary endpo

217 were associated with a significantly better complete response rate (P = .04) and progression-free su

218 Sixty-two patients were enrolled; the complete response rate among all treated patients (n = 6

219 tic delivery reduced local viable tumor, the complete response rate and a subset of tumor immune cell

220 radiotherapy would improve pathological near complete response rate compared with chemoradiotherapy a

221 cell transplantation would improve stringent complete response rate in patients with newly diagnosed

222 ORR was 37.5% with a complete response rate of 12.5%, median progression-free

223 ease, had fewer responses, with pathological complete response rate of 17%(2).

224 The complete response rate of 33.4% after induction in the i

225 The null hypothesis specified a complete response rate of less than 27% in this cohort.

226 The best complete response rate was 100%.

227 The pathological complete response rate was 31% (95% confidence interval:

228 Overall axillary pathologic complete response rate was 37%.

229 60-95) in the triplet therapy group, and the complete response rate was 57% (95% CI 34-78%) in the ip

230 mplete response in >50% of treated mice, the complete response rate was greatest (90%) when 1 week of

231 The significantly higher pathologic complete response rate with NAB-paclitaxel translated in

232 n treating LyP (overall response rate, 100%; complete response rate, 58%), but its use should be rese

233 thout bleomycin or radiation produced a high complete response rate, with most patients requiring onl

234 RCB-0 (pathologic complete response) rate was 53% and RCB-0/I was 63%.

235 Higher rates of very good partial or complete response rates (64% v 39%; hazard ratio [HR], 2

236 % CI, 78.4% to 87.8%), respectively, and the complete response rates at 1 year were 50.5% (n = 192),

237 Pathologic complete response rates have improved on account of more

238 ZUMA-1 trial, which showed best overall and complete response rates in infused patients of 83% and 5

239 Best overall and complete response rates in infused patients were 82% (95

240 Rapid clinical responses and high interim complete response rates to anti-PD1 based first-line tre

241 Complete metabolic/complete response rates were 17% (arm A), 75% (arm B), a

242 was 32%, 10%, and 73%, respectively, and the complete response rates were 23%, 5%, and 55%, respectiv

243 After treatment completion, complete response rates were 56.3% in the NAC arm and 80

244 The overall and complete response rates were 67% and 37%, and with a med

245 R0 and pathologic complete response rates were 96% and 62%, respectively.

246 otherapy significantly improved pathological complete response rates with an acceptable safety profil

247 Despite high complete response rates, relapses occur in a large fract

248 t setting with comparable total pathological complete response rates, supporting the FDA approval.

249 The primary end point was rate of stringent complete response (sCR) after 8 cycles of KRd with a pre

250 The primary end point, stringent complete response (sCR) rate by the end of post-ASCT con

251 erapy improved the rate of pathological near complete response, suggesting that this is a highly acti

252 Interestingly, in cases with a subsequent complete response, the infused CD8(+) CAR T cells had in

253 Among those who achieved a complete response, the median relapse-free survival was

254 o initiated avelumab, four exhibited OR (one complete response, three partial responses; OR rate, 26.

255 NRAS and HRAS mutations showed a partial and complete response to cetuximab, respectively.

256 and/or genomic instability and a partial or complete response to chemotherapy plus bevacizumab combi

257 BEST PRACTICE ADVICE 12: Patients with complete response to HCC therapy who are treated with DA

258 essiveness of recurrent HCC in patients with complete response to HCC therapy.

259 py should not be withheld from patients with complete response to HCC therapy; however, DAA therapy c

260 ted HCV-infected patients who had achieved a complete response to HCC treatment in a North American c

261 In an analysis of nearly 800 patients with complete response to HCC treatment, DAA therapy was asso

262 large cohort of North American patients with complete response to HCC treatment, DAA therapy was not

263 In patients who had partial or complete response to IC, the 5-year DSS probabilities we

264 tatic head and neck cancer who experienced a complete response to immune checkpoint inhibitor therapy

265 2N0 rectal cancer are more likely to develop complete response to neoadjuvant CRT.

266 icipants had an imaging-confirmed partial or complete response to NST and underwent study-specific im

267 In this near-complete response to PD-1 blockade in a mesenchymal tumo

268 Pathological complete response to preoperative treatment in adults wi

269 eive treatment for their HCV infection after complete response to prior HCC therapy.

270 DAA treatment for their HCV infection after complete response to prior HCC therapy.

271 ording to the PERCIST criteria, ranging from complete response to progressive disease.

272 patients with HCV-related HCC who achieved a complete response to resection, local ablation, transart

273 tudy of patients with HCV-related HCC with a complete response to resection, local ablation, transart

274 the classifier genes predicted pathological complete responses to neoadjuvant chemotherapy (P < 0.00

275 ts with stable disease, partial response, or complete response) to therapy.

276 The median follow-up for patients with a complete response was 11.0 months (IQR 5.1-12.4).

277 of stable disease >=6 months and partial or complete response was 26.2% (arm A: 23.2%; arm B: 31.6%

278 survival of patients achieving a pathologic complete response was 83.8 months compared with 20.9 mon

279 ial therapy, in which the primary outcome of complete response was assessed, defined as negative 3-mo

280 Complete response was attained in 60% of 4T07 bearing mi

281 A complete response was attained in 60% of treated mice be

282 the PD-L1-positive population, pathological complete response was documented in 53 (69%, 95% CI 57-7

283 Pathological complete response was documented in 95 (58%, 95% CI 50-6

284 A pathological complete response was noted in 14 (16%) of 87 patients i

285 No partial response or complete response was observed.

286 Pathological complete response was the primary endpoint.

287 Complete responses were also observed against FR-positiv

288 loleucel achieved an objective response, and complete responses were noted in 63 (58%) patients.

289 Completed responses were obtained from 62 of 87 eligible

290 ified 793 patients in the IWWD with clinical complete response who had been managed by a watch-and-wa

291 ancer, achieving a second complete or nearly complete response with chemotherapy, received intraperit

292 The association of complete response with early dermatologic reactions supp

293 %) of 21 patients had a complete response or complete response with incomplete haematological recover

294 phase 2 dose, 14 (70%, 95% CI 46-88) showed complete response with or without complete haematologica

295 as the proportion of patients who achieved a complete response with undetectable minimal residual dis

296 n DAA therapy and time to recurrence after a complete response, with DAA therapy analyzed as a time-v

297 There was no evidence of improvement in complete response within 1 year reported in 27 (46.6%) p

298 without a high-grade Ta or T1 tumour) had a complete response within 3 months of the first dose and

299 uced if they achieve and maintain a clinical complete response within the first 3 years of starting t

300 rther 2 years in patients who had a clinical complete response without distant metastasis for 1 year